Sadeq A Quraishi1, Augusto A Litonjua2, Takuhiro Moromizato3, Fiona K Gibbons4, Carlos A Camargo5, Edward Giovannucci6, Kenneth B Christopher7. 1. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston. 2. Channing Division of Network Medicine and Pulmonary and Critical Care Division Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. The Nathan E. Hellman Memorial Laboratory, Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 4. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston. 5. Department of Emergency Medicine, Massachusetts General Hospital, Boston. 6. Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts. 7. The Nathan E. Hellman Memorial Laboratory, Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts kbchristopher@partners.org.
Abstract
OBJECTIVE: To investigate whether preadmission 25-hydroxyvitamin D (25(OH)D) levels are associated with the risk of hospital-acquired Clostridium difficile infection (HACDI). MATERIALS AND METHODS: Our retrospective cohort study focused on 568 adult patients from 2 Boston teaching hospitals between August 1993 and November 2006. All patients had 25(OH)D levels measured before hospitalization and were at risk for HACDI (defined as the presence of C difficile toxin A or B in stool samples obtained >48 hours after hospitalization). We performed multivariable regression analyses to test the association of prehospital 25(OH)D levels with HACDI while adjusting for clinically relevant covariates. RESULTS: In these 568 patients, mean (SD) 25(OH)D level was 19 (12) ng/mL, and 11% of patients met criteria for incident HACDI. Following adjustment for age, sex, race (nonwhite vs white), patient type (medical vs surgical), and Deyo-Charlson index, patients with 25(OH)D levels <10 ng/mL had higher odds of HACDI (odds ratio [OR], 2.90; 95% confidence interval [CI], 1.01-8.34) compared with patients with 25(OH)D levels ≥30 ng/mL. When patients with HACDI were analyzed relative to a larger patient cohort without HACDI (n = 5047), those with 25(OH)D levels <10 ng/mL (OR, 4.96; 95% CI, 1.84-13.38) and 10-19.9 ng/mL (OR, 3.36; 95% CI, 1.28-8.85) had higher adjusted odds of HACDI compared with patients with 25(OH)D levels ≥30 ng/mL. CONCLUSIONS: In our cohort of adult patients, vitamin D status before hospital admission was inversely associated with the risk of developing HACDI. These data support the need for randomized, controlled trials to test the role of vitamin D supplementation to prevent HACDI.
OBJECTIVE: To investigate whether preadmission 25-hydroxyvitamin D (25(OH)D) levels are associated with the risk of hospital-acquired Clostridium difficileinfection (HACDI). MATERIALS AND METHODS: Our retrospective cohort study focused on 568 adult patients from 2 Boston teaching hospitals between August 1993 and November 2006. All patients had 25(OH)D levels measured before hospitalization and were at risk for HACDI (defined as the presence of C difficile toxin A or B in stool samples obtained >48 hours after hospitalization). We performed multivariable regression analyses to test the association of prehospital 25(OH)D levels with HACDI while adjusting for clinically relevant covariates. RESULTS: In these 568 patients, mean (SD) 25(OH)D level was 19 (12) ng/mL, and 11% of patients met criteria for incident HACDI. Following adjustment for age, sex, race (nonwhite vs white), patient type (medical vs surgical), and Deyo-Charlson index, patients with 25(OH)D levels <10 ng/mL had higher odds of HACDI (odds ratio [OR], 2.90; 95% confidence interval [CI], 1.01-8.34) compared with patients with 25(OH)D levels ≥30 ng/mL. When patients with HACDI were analyzed relative to a larger patient cohort without HACDI (n = 5047), those with 25(OH)D levels <10 ng/mL (OR, 4.96; 95% CI, 1.84-13.38) and 10-19.9 ng/mL (OR, 3.36; 95% CI, 1.28-8.85) had higher adjusted odds of HACDI compared with patients with 25(OH)D levels ≥30 ng/mL. CONCLUSIONS: In our cohort of adult patients, vitamin D status before hospital admission was inversely associated with the risk of developing HACDI. These data support the need for randomized, controlled trials to test the role of vitamin D supplementation to prevent HACDI.
Authors: Ljiljana Bogunovic; Abraham D Kim; Brandon S Beamer; Joseph Nguyen; Joseph M Lane Journal: J Bone Joint Surg Am Date: 2010-10-06 Impact factor: 5.284
Authors: Jordan A Kempker; Bhupesh Panwar; Suzanne E Judd; Nancy S Jenny; Henry E Wang; Orlando M Gutiérrez Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: Diane R Gold; Augusto A Litonjua; Vincent J Carey; JoAnn E Manson; Julie E Buring; I-Min Lee; David Gordon; Joseph Walter; Georgina Friedenberg; John L Hankinson; Trisha Copeland; Heike Luttmann-Gibson Journal: Contemp Clin Trials Date: 2016-01-16 Impact factor: 2.226
Authors: A N Ananthakrishnan; A Cagan; V S Gainer; S-C Cheng; T Cai; P Szolovits; S Y Shaw; S Churchill; E W Karlson; S N Murphy; I Kohane; K P Liao Journal: Aliment Pharmacol Ther Date: 2014-03-18 Impact factor: 8.171
Authors: Jordan A Kempker; Kathryn G West; Russell R Kempker; Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha; Thomas R Ziegler; Greg S Martin Journal: PLoS One Date: 2015-04-07 Impact factor: 3.240
Authors: Travis J Kochan; Madeline J Somers; Alyssa M Kaiser; Michelle S Shoshiev; Ada K Hagan; Jessica L Hastie; Nicole P Giordano; Ashley D Smith; Alyxandria M Schubert; Paul E Carlson; Philip C Hanna Journal: PLoS Pathog Date: 2017-07-13 Impact factor: 6.823
Authors: Dejan Micic; Krishna Rao; Bruno Caetano Trindade; Seth T Walk; Elizabeth Chenoweth; Ruchika Jain; Itishree Trivedi; Kavitha Santhosh; Vincent B Young; David M Aronoff Journal: Infect Dis Rep Date: 2015-09-29
Authors: Bisundev Mahato; Tiffany M N Otero; Carrie A Holland; Patrick T Giguere; Ednan K Bajwa; Carlos A Camargo; Sadeq A Quraishi Journal: J Intensive Care Date: 2016-06-17